US FDA Deems Synapse’s Clinical Trials ‘Unacceptable’

 
• By Urtė Fultinavičiūtė
  
Generate a summary of this article
Listen to this article
Beta

The FDA followed the EMA’s lead and declared Synapse’s trials “unacceptable” forcing drug firms that used CRO’s services to repeat studies to regain therapeutic equivalence ratings.

One line illustration of hangs gestures indicating dispute or disapproval
The FDA downgraded several products to a BX rating after raising data integrity concerns at a CRO. • Source: Shutterstock

Generic drug sponsors who used the contract research organization Synapse may have to repeat bioequivalence trials after the US Food and Drug Administration raised data integrity concerns and determined studies conducted by the firm are not acceptable.

Key Takeaways

  • The FDA raised data integrity concerns at Synapse and downgraded generic drug products that used data from the CRO.

In a 17 June letter, the agency said it has “significant concerns” about the bioequivalence and bioavailability studies conducted...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Generics

Philippines Seeks Feedback On Plan To Recognize BE Studies Under ASEAN Deal

The Philippines medicines regulator explains how it intends to implement the ASEAN mutual recognition agreement under which member states have committed to accept bioequivalence study reports for generics issued by approved BE centers.

Finance Watch: Many Mega-Rounds, Some Smaller VC Deals, But Few In The Middle-Test-Sabbah

 
• By Sabbah

Private Company Edition: June’s eight $100m-plus venture capital rounds already outpace the seven each raised in March, April and May, including €255m ($274.2m) for ITM and $200m for Upstream, but while there were five $25m or less VC financings during the past week, mid-sized deals were lacking.

Novartis Takes Fight To The FDA After US Entresto Generic Approval

 
• By Dean Rudge

Novartis continues to fight tooth and nail to protect its $3bn Entresto brand in the US following the latest FDA approval of a generic version.

Covid

More from Biosimilars & Generics

Facility Deficiencies Drive Rising CRL Rates For CDER Biologics

 
• By Bridget Silverman

A US FDA analysis found that facility inspection issues were the fastest growing factor in the recent rise of complete response letters for biologics licensing applications, in part reflecting the limitations of single-product inspections at contract facilities manufacturing multiple products.

Novartis Takes Fight To The FDA After US Entresto Generic Approval

 
• By Dean Rudge

Novartis continues to fight tooth and nail to protect its $3bn Entresto brand in the US following the latest FDA approval of a generic version.

EU Biosimilar Filings, Opinions And Approvals

 
• By Ian Schofield

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.